Pfizer’s Phase IIIb study with Lyrica (pregabalin) Capsules CV in patients with fibromyalgia (FM), A0081275, met its primary endpoint, showing a reduction in pain in patients who were treated concurrently with antidepressant therapy for comorbid depression. Separately, Phase IIIb study in diabetic peripheral neuropathy DPN pain, A0081269, did not meet its co-primary endpoints by sufficiently reducing DPN pain compared to placebo. The fibromyalgia study (A0081275) was a multicenter, double-blind...